Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors across all previously approved nivolumab indications.
Approval Alert | Subcutaneous Nivolumab in Solid Tumors
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
3
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
4
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
5
